STAND AND DELIVER
Cast Your Vote for One of Three Finalists and Honor Women Who Take a Stand!

Thank you to everyone who submitted a nomination for the STAND AND DELIVER program from Merz Aesthetics, Inc., exclusive distributor of Asclera^® (polidocanol) Injection. The 11-week nomination period closed on Jan. 15, 2012.

The advisory panel has selected three finalists and now you have the opportunity to help us choose the grand prize winner, who will receive $10,000 from Merz Aesthetics and Asclera^® to support her cause, as well as a professional beauty makeover.

Click here to vote for one of the three finalists and automatically be entered into a weekly sweepstakes draw. Voting is open Feb. 20 – April 15, 2012. For more information about the contest and prizes, see the Terms and Conditions.

Meet The Finalists

To learn more about the finalists who were selected by the advisory panel and vote for your favorite, click the images below. Please note these women are not being treated with Asclera^®.

Michelle Rubin
Director,
Autism After 21

Carol Burnett
Community Outreach/Recruitment Coordinator
Long Island Head Start

Sara Finger
Executive Director
Wisconsin Alliance for Women's Health

Time Left to Vote

Cast your vote Feb. 20, 2012 through April 15, 2012.



Days	Hours	Minutes	Seconds

To receive an alert when the winner is announced, please enter your email:

Show your support for the STAND AND DELIVER program.

How Can You Help?

Cast your vote for one of our three finalists by April 15, 2012!

Talk to your doctor about Asclera^® for the treatment of uncomplicated spider veins and uncomplicated reticular veins.*

Proceeds from your treatment will help fund the $10,000 contribution to the winner's charity.

To find an Asclera^® provider near you, please enter your zip code:

*Asclera^® is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera^® has not been studied in varicose veins more than 3 mm in diameter.

About Stand & Deliver

Cast Your Vote

Meet the Finalists

Meet The Advisory Panel

Contest Terms & Conditions

About Asclera®

IMPORTANT SAFETY INFORMATION FOR PATIENTS:

For intravenous use only.

CONTRAINDICATIONS: Asclera^® (polidocanol) Injection is contraindicated for patients with known allergy (anaphylaxis) to polidocanol and patients with acute vein and blood clotting diseases.

WARNINGS AND PRECAUTIONS:
Anaphylaxis: Severe allergic reactions have been reported following polidocanol use, including anaphylactic reactions, some of them fatal. Severe reactions are most frequent with use of larger volumes (> 3 mL). The dose of polidocanol should therefore be minimized.Please notify your healthcare provider if you have a known history of severe allergies or allergy to polidocanol.

Accidental injection into an artery can cause severe necrosis, ischemia or gangrene. If this occurs, consult your healthcare provider or a vascular surgeon immediately.

Unintentional injection of Asclera outside of the vein can cause pain. If pain is severe, a local anesthetic (without adrenaline) may be injected by your healthcare provider.

Severe adverse local effects, including tissue necrosis, may occur following flow of the product outside of the vein; therefore, the smallest effective volume at each injection site should be used.

After the injection session is completed, apply compression with a stocking or bandage, and walk for 15- 20 minutes. Your healthcare provider will provide monitoring during this period to treat any possible anaphylactic or allergic reactions.

Maintain compression for 2 to 3 days after treatment of spider veins and for 5 to 7 days for reticular veins, or as directed by your Healthcare Provider. For extensive varicosities, longer compression treatment with compression bandages or a gradient compression stocking of a higher compression class is recommended. Post-treatment compression is necessary to reduce the risk of deep vein thrombosis.

ADVERSE REACTIONS: In clinical studies, the following adverse reactions were observed after using Asclera^® and were more common with Asclera^® than placebo: injection site hematoma, injection site irritation, injection site discoloration, injection site pain, injection site itching, injection site warmth, neovascularization, injection site clotting.

You are encouraged to report any suspected adverse events. To report SUSPECTED ADVERSE REACTIONS, contact your Healthcare Provider, Merz Aesthetics at 1-866-862-1211, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

IMPORTANT SAFETY INFORMATION FOR HEALTHCARE PROVIDERS:

For intravenous use only.

CONTRAINDICATIONS: Asclera^® (polidocanol) Injection is contraindicated for patients with known allergy (anaphylaxis) to polidocanol and patients with acute thromboembolic diseases.

WARNINGS AND PRECAUTIONS:
Anaphylaxis: Severe allergic reactions have been reported following polidocanol use, including anaphylactic reactions, some of them fatal. Severe reactions are most frequent with use of larger volumes (> 3 mL). The dose of polidocanol should therefore be minimized. Be prepared to treat anaphylaxis appropriately.

Accidental Intra-arterial injection can cause severe necrosis, ischemia or gangrene. If this occurs, consult a vascular surgeon immediately.

Inadvertent Perivascular Injection of Asclera^® can cause pain. If pain is severe, a local anesthetic (without adrenaline) may be injected.

Severe adverse local effects, including tissue necrosis, may occur following extravasation; therefore, take care in intravenous needle placement and the smallest effective volume at each injection site should be used.

After the injection session is completed, apply compression with a stocking or bandage, and have the patient walk for 15-20 minutes. Keep the patient under supervision during this period to treat any anaphylactic or allergic reaction.

Maintain compression for 2 to 3 days after treatment of spider veins and for 5 to 7 days for reticular veins. For extensive varicosities, longer compression treatment with compression bandages or a gradient compression stocking of a higher compression class is recommended. Post-treatment compression is necessary to reduce the risk of deep vein thrombosis.

ADVERSE REACTIONS: In clinical studies, the following adverse reactions were observed after using Asclera^® and were more common with Asclera^® than placebo: injection site haematoma, injection site irritation, injection site discoloration, injection site pain, injection site pruritus, injection site warmth, neovascularization, injection site thrombosis.